TNF and neoplasm: Weekly or three-weekly dosing was well tolerated at doses up to 3700 mg m–2 and, in addition to the DCE-MRI changes, elevated tumour but not serum TNF levels and plasma serotonin metabolite levels were observed, consistent with preclinical data (M Jameson and GJ Rustin, personal communications).